WO2007044616A3 - Optimized anti-cd30 antibodies - Google Patents
Optimized anti-cd30 antibodies Download PDFInfo
- Publication number
- WO2007044616A3 WO2007044616A3 PCT/US2006/039306 US2006039306W WO2007044616A3 WO 2007044616 A3 WO2007044616 A3 WO 2007044616A3 US 2006039306 W US2006039306 W US 2006039306W WO 2007044616 A3 WO2007044616 A3 WO 2007044616A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- antibodies
- optimized anti
- parent
- fcgr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Abstract
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2006302254A AU2006302254B2 (en) | 2005-10-06 | 2006-10-06 | Optimized anti-CD30 antibodies |
US12/089,384 US7973136B2 (en) | 2005-10-06 | 2006-10-06 | Optimized anti-CD30 antibodies |
EP06825618.9A EP1951757B1 (en) | 2005-10-06 | 2006-10-06 | Optimized anti-cd30 antibodies |
JP2008534748A JP4860703B2 (en) | 2005-10-06 | 2006-10-06 | Optimized anti-CD30 antibody |
CA2625998A CA2625998C (en) | 2005-10-06 | 2006-10-06 | Optimized anti-cd30 antibodies |
AU2011202115A AU2011202115A1 (en) | 2005-10-06 | 2011-05-09 | Optimized Anti-CD30 Antibodies |
US13/163,465 US9574006B2 (en) | 2005-10-06 | 2011-06-17 | Optimized anti-CD30 antibodies |
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72462405P | 2005-10-06 | 2005-10-06 | |
US60/724,624 | 2005-10-06 | ||
US73799805P | 2005-11-18 | 2005-11-18 | |
US60/737,998 | 2005-11-18 | ||
US75069705P | 2005-12-15 | 2005-12-15 | |
US60/750,697 | 2005-12-15 | ||
US77659806P | 2006-02-24 | 2006-02-24 | |
US60/776,598 | 2006-02-24 | ||
US74553606P | 2006-04-25 | 2006-04-25 | |
US60/745,536 | 2006-04-25 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/089,384 A-371-Of-International US7973136B2 (en) | 2005-10-06 | 2006-10-06 | Optimized anti-CD30 antibodies |
US13/163,465 Division US9574006B2 (en) | 2005-10-06 | 2011-06-17 | Optimized anti-CD30 antibodies |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007044616A2 WO2007044616A2 (en) | 2007-04-19 |
WO2007044616A3 true WO2007044616A3 (en) | 2007-07-12 |
Family
ID=37943433
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/039306 WO2007044616A2 (en) | 2005-10-06 | 2006-10-06 | Optimized anti-cd30 antibodies |
Country Status (6)
Country | Link |
---|---|
US (2) | US7973136B2 (en) |
EP (1) | EP1951757B1 (en) |
JP (1) | JP4860703B2 (en) |
AU (2) | AU2006302254B2 (en) |
CA (1) | CA2625998C (en) |
WO (1) | WO2007044616A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8852586B2 (en) | 2004-11-12 | 2014-10-07 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US9200079B2 (en) | 2004-11-12 | 2015-12-01 | Xencor, Inc. | Fc variants with altered binding to FcRn |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
US9714282B2 (en) | 2003-09-26 | 2017-07-25 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
EP1697741A4 (en) | 2003-12-04 | 2008-02-13 | Xencor Inc | Methods of generating variant proteins with increased host string content and compositions thereof |
CA2624189A1 (en) * | 2005-10-03 | 2007-04-12 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
CA2625998C (en) | 2005-10-06 | 2015-12-01 | Xencor, Inc. | Optimized anti-cd30 antibodies |
US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
EP2200634B1 (en) * | 2007-09-21 | 2015-02-11 | The Regents of The University of California | Targeted interferon demonstrates potent apoptotic and anti-tumor activities |
US9096651B2 (en) | 2007-09-26 | 2015-08-04 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
NZ584552A (en) * | 2007-10-12 | 2012-07-27 | Seattle Genetics Inc | Combination therapy comprising brentuximab and either a AVBD regimen or gemcitabine |
WO2009062083A2 (en) * | 2007-11-08 | 2009-05-14 | Pikamab, Inc. | Methods and compositions for antibody therapy |
ES2742268T3 (en) | 2007-12-26 | 2020-02-13 | Xencor Inc | Fc variants with altered FcRn binding |
LT2708559T (en) | 2008-04-11 | 2018-06-11 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
HUE042901T2 (en) | 2008-09-17 | 2019-07-29 | Xencor Inc | Compositions and methods for treating ige-mediated disorders |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
BR112012021261A2 (en) | 2010-02-23 | 2020-01-07 | Sanofi | HUMANIZED ANTI-ALFA2 INTEGRIN ANTIBODY, USE OF THE SAME, ISOLATED NUCLEIC ACID ENCODING AN ANTI-ALFA2BETA1 INTEGRIN ANTIBODY, VECTOR, HOST CELL, COMPOSITION, KIT AND ANTIBODY |
CA2799595C (en) | 2010-05-27 | 2022-08-16 | Merck Sharp & Dohme Corp. | Method for preparing antibodies having improved properties |
TWI560199B (en) | 2010-08-31 | 2016-12-01 | Sanofi Sa | Peptide or peptide complex binding to α2 integrin and methods and uses involving the same |
TWI812066B (en) | 2010-11-30 | 2023-08-11 | 日商中外製藥股份有限公司 | Antibody having calcium-dependent antigen-binding ability |
US9541480B2 (en) | 2011-06-29 | 2017-01-10 | Academia Sinica | Capture, purification, and release of biological substances using a surface coating |
US20150079075A1 (en) * | 2011-09-15 | 2015-03-19 | Cytodyn Inc. | Anti-CD11A Antibodies and Uses Thereof |
ES2725569T3 (en) | 2012-02-10 | 2019-09-24 | Seattle Genetics Inc | Diagnosis and treatment of cancers that express CD30 |
TW202237660A (en) | 2012-08-24 | 2022-10-01 | 日商中外製藥股份有限公司 | Fcγriib-specific fc region variant |
WO2014030750A1 (en) | 2012-08-24 | 2014-02-27 | 中外製薬株式会社 | MOUSE FcγRII-SPECIFIC Fc ANTIBODY |
WO2014089354A1 (en) | 2012-12-07 | 2014-06-12 | The Regents Of The University Of California | Cd138-targeted interferon demonstrates potent apoptotic and anti-tumor activities |
AU2014250434B2 (en) | 2013-04-02 | 2019-08-08 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
WO2014194100A1 (en) | 2013-05-29 | 2014-12-04 | The Regents Of The University Of California | Anti-cspg4 fusions with interferon for the treatment of malignancy |
BR112016021777A2 (en) * | 2014-03-24 | 2017-10-03 | Biogen Ma Inc | LYOPHILIZED FACTOR IX FORMULATIONS |
WO2015153816A2 (en) | 2014-04-01 | 2015-10-08 | Academia Sinica | Methods and systems for cancer diagnosis and prognosis |
US10112198B2 (en) | 2014-08-26 | 2018-10-30 | Academia Sinica | Collector architecture layout design |
KR102650420B1 (en) | 2014-12-19 | 2024-03-21 | 추가이 세이야쿠 가부시키가이샤 | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
SG10201907215QA (en) | 2015-02-05 | 2019-09-27 | Chugai Pharmaceutical Co Ltd | Antibodies Comprising An Ion Concentration Dependent Antigen-Binding Domain, Fc Region Variants, Il-8-Binding Antibodies, And Uses Therof |
KR20170109052A (en) * | 2015-02-06 | 2017-09-27 | 내셔널 유니버시티 오브 싱가포르 | Improving the efficacy of therapeutic immune cells |
AR104368A1 (en) | 2015-04-03 | 2017-07-19 | Lilly Co Eli | ANTI-CD20- / ANTI-BAFF BIESPECTIFIC ANTIBODIES |
EP3362476B1 (en) | 2015-10-15 | 2020-05-27 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Anti-cd30 chimeric antigen receptors |
WO2017110981A1 (en) | 2015-12-25 | 2017-06-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
US10107726B2 (en) | 2016-03-16 | 2018-10-23 | Cellmax, Ltd. | Collection of suspended cells using a transferable membrane |
CN116271014A (en) | 2016-08-05 | 2023-06-23 | 中外制药株式会社 | Compositions for preventing or treating IL-8 related diseases |
SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
KR20190085528A (en) | 2016-11-22 | 2019-07-18 | 싱가포르국립대학교 | Blocking chimeric antigen receptors and CD7 expression for immunotherapy of T-cell malignancies |
JP7373998B2 (en) | 2017-05-02 | 2023-11-06 | コーネル・ユニバーシティー | Tumor targeting methods and reagents with greater efficacy and less toxicity |
KR20200035304A (en) | 2017-08-10 | 2020-04-02 | 싱가포르국립대학교 | T cell receptor-deficient chimeric antigen receptor T-cells and methods of use thereof |
CN112119090B (en) | 2018-03-15 | 2023-01-13 | 中外制药株式会社 | Anti-dengue virus antibodies cross-reactive to Zika virus and methods of use |
WO2019234576A1 (en) | 2018-06-03 | 2019-12-12 | Lamkap Bio Beta Ltd. | Bispecific antibodies against ceacam5 and cd47 |
EP3831849A1 (en) | 2019-12-02 | 2021-06-09 | LamKap Bio beta AG | Bispecific antibodies against ceacam5 and cd47 |
WO2021221927A1 (en) | 2020-04-27 | 2021-11-04 | Parsons Corporation | Narrowband iq signal obfuscation |
JP2023528632A (en) | 2020-06-05 | 2023-07-05 | テッサ・セラピューティクス・リミテッド | Treatment of CD30 positive cancer |
US20240000979A1 (en) * | 2020-10-01 | 2024-01-04 | Cornell University | Methods and compositions for synergistic uptake and retention of small molecule ligands |
WO2022074206A1 (en) | 2020-10-08 | 2022-04-14 | Affimed Gmbh | Trispecific binders |
EP4255497A1 (en) * | 2020-12-03 | 2023-10-11 | Seagen Inc. | Modulating the immune response using anti-cd30 antibody-drug conjugates |
IL301701A (en) | 2020-12-18 | 2023-05-01 | Lamkap Bio Beta Ag | Bispecific antiodies against ceacam5 and cd47 |
WO2022136705A1 (en) * | 2020-12-24 | 2022-06-30 | Synaffix B.V. | Glycan-conjugated antibodies binding to fc-gamma receptor |
CA3218235A1 (en) | 2021-04-27 | 2022-11-03 | Baylor College Of Medicine | Virus-specific immune cells expressing chimeric antigen receptors |
IL308154A (en) | 2021-07-30 | 2023-12-01 | Affimed Gmbh | Duplexbodies |
WO2023028162A1 (en) * | 2021-08-25 | 2023-03-02 | Biograph 55, Inc. | Antibodies targeting immunosuppressive b cells |
WO2023072953A1 (en) | 2021-10-26 | 2023-05-04 | Tessa Therapeutics Ltd. | Cell lines for producing a retroviral vector encoding a car |
TW202334221A (en) | 2021-11-03 | 2023-09-01 | 德商安富美德有限公司 | Bispecific cd16a binders |
WO2023104910A1 (en) | 2021-12-08 | 2023-06-15 | Tessa Therapeutics Ltd. | Treatment of lymphoma |
WO2023198744A1 (en) | 2022-04-13 | 2023-10-19 | Tessa Therapeutics Ltd. | Therapeutic t cell product |
WO2023242351A1 (en) | 2022-06-16 | 2023-12-21 | Lamkap Bio Beta Ag | Combination therapy of bispecific antibodies against ceacam5 and cd47 and bispecific antibodies against ceacam5 and cd3 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003059282A2 (en) * | 2002-01-09 | 2003-07-24 | Medarex, Inc. | Human monoclonal antibodies against cd30 |
WO2004029207A2 (en) * | 2002-09-27 | 2004-04-08 | Xencor Inc. | Optimized fc variants and methods for their generation |
WO2005056606A2 (en) * | 2003-12-03 | 2005-06-23 | Xencor, Inc | Optimized antibodies that target the epidermal growth factor receptor |
WO2005056759A2 (en) * | 2003-12-04 | 2005-06-23 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
Family Cites Families (154)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
CA1340935C (en) | 1986-05-29 | 2000-03-28 | Ian F.C. Mckenzie | Fc gamma receptor |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
NZ226414A (en) | 1987-10-02 | 1992-07-28 | Genentech Inc | Cd4 peptide adhesion variants and their preparation and use |
US5576184A (en) | 1988-09-06 | 1996-11-19 | Xoma Corporation | Production of chimeric mouse-human antibodies with specificity to human tumor antigens |
US20030229208A1 (en) | 1988-12-28 | 2003-12-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5266491A (en) | 1989-03-14 | 1993-11-30 | Mochida Pharmaceutical Co., Ltd. | DNA fragment and expression plasmid containing the DNA fragment |
JP3051411B2 (en) | 1989-03-14 | 2000-06-12 | 持田製薬株式会社 | Novel DNA and expression plasmid containing it |
PT95809A (en) | 1989-11-07 | 1991-09-13 | Bristol Myers Squibb Co | METHOD FOR THE PREPARATION OF OLIGOMERIC IMMUNOGLOBULINS, IN ADDITION, OLIGOMERIC MONOCLONAL ANTIBODIES |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
WO1991019515A1 (en) | 1990-06-21 | 1991-12-26 | The Board Of Trustees Of The Leland Stanford Junior University | Oligomeric immunoglobulin constant domain mutant with enhanced complement-mediated cytolytic activity |
US5198342A (en) | 1990-07-05 | 1993-03-30 | Immunex Corporation | DNA encoding IgA Fc receptors |
WO1992004053A1 (en) | 1990-08-31 | 1992-03-19 | Bristol-Myers Sqibb Company | Homoconjugated immunoglobulins |
GB9022545D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Culture medium |
GB9105245D0 (en) | 1991-03-12 | 1991-04-24 | Lynxvale Ltd | Binding molecules |
US6797492B2 (en) | 1991-05-17 | 2004-09-28 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
WO1992022324A1 (en) | 1991-06-14 | 1992-12-23 | Xoma Corporation | Microbially-produced antibody fragments and their conjugates |
DE69233254T2 (en) | 1991-06-14 | 2004-09-16 | Genentech, Inc., South San Francisco | Humanized Heregulin antibody |
JP3951062B2 (en) | 1991-09-19 | 2007-08-01 | ジェネンテック・インコーポレーテッド | Expression of antibody fragments with cysteine present at least as a free thiol in E. coli for the production of bifunctional F (ab ') 2 antibodies |
US5623053A (en) | 1992-01-10 | 1997-04-22 | California Institute Of Technology | Soluble mammal-derived Fc receptor which binds at a pH ranging from about 5.5 to 6.5 and releases at a pH ranging from about 7.5 to 8.5 |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
US20030108548A1 (en) | 1993-06-01 | 2003-06-12 | Bluestone Jeffrey A. | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
GB9316989D0 (en) | 1993-08-16 | 1993-09-29 | Lynxvale Ltd | Binding molecules |
CA2186455A1 (en) | 1994-03-29 | 1995-10-05 | Raymond John Owens | Antibodies against e-selectin |
US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
US6030613A (en) | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
ATE238668T1 (en) | 1995-01-17 | 2003-05-15 | Brigham & Womens Hospital | RECEPTOR-SPECIFIC TRANSEPITHELIAL TRANSPORT OF IMMUNOGENS |
US6485726B1 (en) | 1995-01-17 | 2002-11-26 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
US6086875A (en) | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
EP0805871B2 (en) | 1995-01-18 | 2006-02-22 | Roche Diagnostics GmbH | Anti-cd30 antibodies preventing proteolytic cleavage and release of membrane-bound cd30 antigen |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6444789B1 (en) | 1995-05-03 | 2002-09-03 | Applied Research Systems Ars Holding N.V. | CD16-II variants |
US6365161B1 (en) | 1995-06-07 | 2002-04-02 | Medarex, Inc. | Therapeutic compounds comprised of anti-FC receptor binding agents |
US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
DE69731289D1 (en) | 1996-03-18 | 2004-11-25 | Univ Texas | IMMUNGLOBULIN-LIKE DOMAIN WITH INCREASED HALF-VALUE TIMES |
JP3904238B2 (en) | 1996-03-20 | 2007-04-11 | イムノメディクス, インコーポレイテッド | Glycosylated humanized B cell specific antibody |
US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
DE69726003T2 (en) | 1996-07-16 | 2004-08-26 | Andreas Plückthun | IMMUNGLOBULIN SUPERFAMILY DOMAINS AND FRAGMENTS WITH INCREASED SOLUBILITY |
ES2300113T3 (en) | 1996-08-02 | 2008-06-01 | Bristol-Myers Squibb Company | A PROCEDURE FOR INHIBITING TOXICITY INDUCED BY IMMUNOGLOBULINS RESULTING FROM THE USE OF IMMUNOGLOBULINS IN THERAPY AND IN VIVO DIAGNOSIS. |
WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
AU5927398A (en) | 1997-01-21 | 1998-08-07 | Human Genome Sciences, Inc. | Fc receptors and polypeptides |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
EP1255209A3 (en) | 1997-04-11 | 2009-02-11 | California Institute Of Technology | Apparatus and method for automated protein design |
CA2286262A1 (en) | 1997-04-11 | 1998-10-22 | California Institute Of Technology | Apparatus and method for automated protein design |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
US20040191256A1 (en) | 1997-06-24 | 2004-09-30 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
US20030105294A1 (en) | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
EP1068241B1 (en) | 1998-04-02 | 2007-10-10 | Genentech, Inc. | Antibody variants and fragments thereof |
US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
ES2434961T5 (en) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Antibody glycosylation engineering to improve antibody-dependent cell cytotoxicity |
EP1082137A4 (en) | 1998-05-06 | 2004-05-19 | Univ Temple | REVERSAL OF PROINFLAMMATORY RESPONSE BY LIGATING THE MACROPHAGE Fc$g(g)RI RECEPTOR |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
US20020142374A1 (en) | 1998-08-17 | 2002-10-03 | Michael Gallo | Generation of modified molecules with increased serum half-lives |
US6306926B1 (en) | 1998-10-07 | 2001-10-23 | 3M Innovative Properties Company | Radiopaque cationically polymerizable compositions comprising a radiopacifying filler, and method for polymerizing same |
US20030049654A1 (en) | 1998-10-16 | 2003-03-13 | Xencor | Protein design automation for protein libraries |
JP2003527072A (en) | 1998-10-16 | 2003-09-16 | ゼンコー | Protein design automation for protein libraries |
US20020048772A1 (en) | 2000-02-10 | 2002-04-25 | Dahiyat Bassil I. | Protein design automation for protein libraries |
US7315786B2 (en) | 1998-10-16 | 2008-01-01 | Xencor | Protein design automation for protein libraries |
US6403312B1 (en) | 1998-10-16 | 2002-06-11 | Xencor | Protein design automatic for protein libraries |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
CN1763097B (en) | 1999-01-15 | 2011-04-13 | 杰南技术公司 | Polypeptide variants with altered effector function |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
ES2420835T3 (en) | 1999-04-09 | 2013-08-27 | Kyowa Hakko Kirin Co., Ltd. | Procedure to control the activity of immunofunctional molecules |
US6638515B2 (en) | 1999-09-07 | 2003-10-28 | Walter Schubert | Method of blocking cytotoxic activity in patients with amyotrophic lateral sclerosis using protein V |
WO2001029246A1 (en) | 1999-10-19 | 2001-04-26 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing polypeptide |
ES2586850T3 (en) | 1999-11-29 | 2016-10-19 | The Trustees Of Columbia University In The City Of New York | Isolation of five novel genes encoding new Fc receptor-type melanomas involved in the pathogenesis of lymphoma / melanoma |
US20060272036A1 (en) | 2000-02-03 | 2006-11-30 | Lennart Hammarstrom | Ruminant mhc class-i-like fc receptors |
WO2001059066A2 (en) | 2000-02-10 | 2001-08-16 | Xencor, Inc. | Protein design automation for protein libraries |
BR0110610A (en) | 2000-04-11 | 2003-04-29 | Genentech Inc | Isolated antibodies, immunoconjugates, polypeptide chains, isolated nucleic acid, vector, host cell, antibody or polypeptide chain production process, method of treating mammalian dysfunction, method of inducing apoptosis of a cancer cell, method of killing a cell b, method for killing a cell expressing an erbb receptor and uses of isolated antibodies |
WO2001079299A1 (en) | 2000-04-13 | 2001-10-25 | The Rockefeller University | Enhancement of antibody-mediated immune responses |
US6358733B1 (en) | 2000-05-19 | 2002-03-19 | Apolife, Inc. | Expression of heterologous multi-domain proteins in yeast |
US20020106368A1 (en) | 2000-07-28 | 2002-08-08 | Adrian Bot | Novel methods and compositions to upregulate, redirect or limit immune responses to peptides, proteins and other bioactive compounds and vectors expressing the same |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
ES2620359T3 (en) | 2000-10-06 | 2017-06-28 | Kyowa Hakko Kirin Co., Ltd. | Cells that produce antibody compositions |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
WO2002030954A1 (en) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kogyo Co., Ltd. | Method of purifying antibody |
US7465790B2 (en) | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
US6992234B2 (en) | 2000-11-06 | 2006-01-31 | The Jackson Laboratory | FcRn-based therapeutics for the treatment of auto-immune disorders |
US7235643B2 (en) | 2000-11-07 | 2007-06-26 | Morphotek, Inc. | Antibodies and methods for generating genetically altered antibodies with high affinity |
US20070258987A1 (en) * | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
US7090843B1 (en) | 2000-11-28 | 2006-08-15 | Seattle Genetics, Inc. | Recombinant anti-CD30 antibodies and uses thereof |
US20040018194A1 (en) * | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
GB0029407D0 (en) | 2000-12-01 | 2001-01-17 | Affitech As | Product |
US20040253242A1 (en) | 2000-12-05 | 2004-12-16 | Bowdish Katherine S. | Rationally designed antibodies |
PT1355919E (en) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Molecules with extended half-lives, compositions and uses thereof |
DE60135498D1 (en) | 2000-12-14 | 2008-10-02 | Genentech Inc | Production of Whole Antibodies in Prokaryotic Cells |
US6979556B2 (en) | 2000-12-14 | 2005-12-27 | Genentech, Inc. | Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
WO2002061093A1 (en) | 2001-01-30 | 2002-08-08 | Degussa Ag | Nucleotide sequences which code for the otsa gene of c. glutamicum |
GB0118662D0 (en) | 2001-07-31 | 2001-09-19 | Univ Southampton | Binding agents |
KR20100018071A (en) | 2001-08-03 | 2010-02-16 | 글리카트 바이오테크놀로지 아게 | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
WO2003014325A2 (en) | 2001-08-10 | 2003-02-20 | Xencor | Protein design automation for protein libraries |
WO2003016470A2 (en) | 2001-08-10 | 2003-02-27 | University Of Virginia Patent Foundation | Enhancing the efficacy of immunotherapies by supplementing with complement |
US20030157108A1 (en) | 2001-10-25 | 2003-08-21 | Genentech, Inc. | Glycoprotein compositions |
CN1292655C (en) | 2001-11-08 | 2007-01-03 | 蛋白质设计实验室股份有限公司 | Stable liquid pharmaceutical formulation of IgG antibodies |
US6911321B2 (en) | 2001-12-19 | 2005-06-28 | Genentech, Inc. | Non-human primate Fc receptors and methods of use |
AU2003216250A1 (en) | 2002-02-11 | 2003-09-04 | Genentech, Inc. | Antibody variants with faster antigen association rates |
US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US20070148171A1 (en) | 2002-09-27 | 2007-06-28 | Xencor, Inc. | Optimized anti-CD30 antibodies |
US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
AU2003217912A1 (en) | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
CN101143221A (en) | 2002-03-15 | 2008-03-19 | 布赖汉姆妇女医院 | Central airway administration for systemic delivery of therapeutics |
JP2005521429A (en) | 2002-03-25 | 2005-07-21 | ユーエービー リサーチ ファウンデーション | Fc receptor homologues, reagents and uses thereof |
WO2003085119A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa |
WO2004004798A2 (en) | 2002-07-03 | 2004-01-15 | The Brigham And Women's Hospital, Inc. | Central airway administration for systemic delivery of therapeutics |
WO2004004662A2 (en) | 2002-07-09 | 2004-01-15 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
WO2004016750A2 (en) | 2002-08-14 | 2004-02-26 | Macrogenics, Inc. | FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF |
AU2003270369A1 (en) | 2002-09-05 | 2004-03-29 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Minimally immunogenic variants of humanized col-1 antibody against carcinoembryonic antigen |
JP2005539067A (en) | 2002-09-16 | 2005-12-22 | エリューシス セラピューティクス,インコーポレーテッド | Production of bispecific molecules using polyethylene glycol linkers |
WO2004035752A2 (en) | 2002-10-15 | 2004-04-29 | Protein Design Labs, Inc. | ALTERATION OF FcRn BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS |
US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
US7365168B2 (en) | 2002-10-15 | 2008-04-29 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
BRPI0316779B8 (en) | 2002-12-16 | 2023-02-28 | Genentech Inc | HUMAN ANTI-CD20 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, ITS USES, COMPOSITION, MANUFACTURED ARTICLE AND LIQUID FORMULATION |
US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
US8388955B2 (en) * | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
US20070275460A1 (en) * | 2003-03-03 | 2007-11-29 | Xencor.Inc. | Fc Variants With Optimized Fc Receptor Binding Properties |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
AR044388A1 (en) | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | CD20 UNION MOLECULES |
JP2007501021A (en) | 2003-05-30 | 2007-01-25 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | Antibodies and fusion proteins containing genetically engineered constant regions |
BRPI0411112A (en) | 2003-06-12 | 2006-07-18 | Lilly Co Eli | heterologous fusion protein, polynucleotide, vector, host cell, process for producing a heterologous fusion protein, method for treating a patient, and use of heterologous fusion protein |
NZ544923A (en) | 2003-06-27 | 2009-02-28 | Biogen Idec Inc | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous anti-body solutions |
EP1644416A4 (en) | 2003-06-30 | 2007-08-29 | Centocor Inc | Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses |
SI1648507T1 (en) | 2003-07-24 | 2017-07-31 | Innate Pharma S.A. | Methods and compositions for increasing the efficiency of therapeutic antibodies using nk cell potentiating compounds |
JP4944608B2 (en) | 2003-07-26 | 2012-06-06 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Altered antibodies with improved antigen binding affinity |
WO2005013090A2 (en) | 2003-08-01 | 2005-02-10 | Dna Twopointo Inc. | Systems and methods for biopolymer engineering |
CN1871259A (en) | 2003-08-22 | 2006-11-29 | 比奥根艾迪克Ma公司 | Improved antibodies having altered effector function and methods for making the same |
AU2004273791A1 (en) | 2003-09-05 | 2005-03-31 | Genentech, Inc. | Antibodies with altered effector functions |
WO2005023866A2 (en) | 2003-09-10 | 2005-03-17 | Baxter International Inc. | Peptides that inhibit complement activation |
JP2005159294A (en) * | 2003-09-18 | 2005-06-16 | Nec Kagoshima Ltd | Method of treating substrate and chemical used therefor |
US20060134105A1 (en) * | 2004-10-21 | 2006-06-22 | Xencor, Inc. | IgG immunoglobulin variants with optimized effector function |
WO2005037867A1 (en) | 2003-10-15 | 2005-04-28 | Pdl Biopharma, Inc. | ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG |
GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
WO2005063815A2 (en) | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
EP2385069A3 (en) | 2003-11-12 | 2012-05-30 | Biogen Idec MA Inc. | Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto |
PL1706424T3 (en) | 2004-01-12 | 2010-04-30 | Mentrik Biotech Llc | Fc region variants |
WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
KR100545720B1 (en) | 2004-05-31 | 2006-01-24 | 메덱스젠 주식회사 | Glycosylated Immunoglobulin and Immunoadhesin comprising the same |
AU2005267020B2 (en) | 2004-07-23 | 2011-08-11 | Genentech, Inc. | Crystallization of antibodies or fragments thereof |
CA2625998C (en) | 2005-10-06 | 2015-12-01 | Xencor, Inc. | Optimized anti-cd30 antibodies |
US9098105B2 (en) | 2012-08-24 | 2015-08-04 | Avago Technologies General Ip (Singapore) Pte. Ltd. | Dynamic Y-buffer size adjustment for retained sector reprocessing |
US9703321B2 (en) | 2013-07-09 | 2017-07-11 | I-Blades, Inc. | Snap on wearable module |
US9721437B2 (en) | 2014-11-09 | 2017-08-01 | Interblock D.D. | Slot machine with secondary game content |
-
2006
- 2006-10-06 CA CA2625998A patent/CA2625998C/en active Active
- 2006-10-06 WO PCT/US2006/039306 patent/WO2007044616A2/en active Application Filing
- 2006-10-06 JP JP2008534748A patent/JP4860703B2/en active Active
- 2006-10-06 EP EP06825618.9A patent/EP1951757B1/en active Active
- 2006-10-06 AU AU2006302254A patent/AU2006302254B2/en not_active Ceased
- 2006-10-06 US US12/089,384 patent/US7973136B2/en active Active
-
2011
- 2011-05-09 AU AU2011202115A patent/AU2011202115A1/en not_active Abandoned
- 2011-06-17 US US13/163,465 patent/US9574006B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003059282A2 (en) * | 2002-01-09 | 2003-07-24 | Medarex, Inc. | Human monoclonal antibodies against cd30 |
WO2004029207A2 (en) * | 2002-09-27 | 2004-04-08 | Xencor Inc. | Optimized fc variants and methods for their generation |
WO2005056606A2 (en) * | 2003-12-03 | 2005-06-23 | Xencor, Inc | Optimized antibodies that target the epidermal growth factor receptor |
WO2005056759A2 (en) * | 2003-12-04 | 2005-06-23 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
Non-Patent Citations (3)
Title |
---|
SHIELDS R L ET AL: "High resolution mapping of the binding site on human IgG1 for FcgammaRI, FcgammaRII, FcgammaRIII, and FcRn and design of IgG1 variants with improved binding to the FcgammaR", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 276, no. 9, 2 March 2001 (2001-03-02), pages 6591 - 6604, XP002271092, ISSN: 0021-9258 * |
SHINKAWA T ET AL: "The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 278, no. 5, 31 January 2003 (2003-01-31), pages 3466 - 3473, XP002355427, ISSN: 0021-9258 * |
YAMANE-OHNUKI N ET AL: "Establishment of FUT8 knockout chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity", BIOTECHNOLOGY AND BIOENGINEERING, INTERSCIENCE PUBLISHERS, LONDON, GB, vol. 87, no. 5, 5 September 2004 (2004-09-05), pages 614 - 622, XP002983153, ISSN: 0006-3592 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8852586B2 (en) | 2004-11-12 | 2014-10-07 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8883973B2 (en) | 2004-11-12 | 2014-11-11 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US9200079B2 (en) | 2004-11-12 | 2015-12-01 | Xencor, Inc. | Fc variants with altered binding to FcRn |
Also Published As
Publication number | Publication date |
---|---|
US20080267976A1 (en) | 2008-10-30 |
AU2006302254B2 (en) | 2011-05-26 |
JP2009511495A (en) | 2009-03-19 |
EP1951757A2 (en) | 2008-08-06 |
US9574006B2 (en) | 2017-02-21 |
EP1951757B1 (en) | 2014-05-14 |
AU2006302254A1 (en) | 2007-04-19 |
JP4860703B2 (en) | 2012-01-25 |
US20120014943A1 (en) | 2012-01-19 |
CA2625998C (en) | 2015-12-01 |
WO2007044616A2 (en) | 2007-04-19 |
AU2011202115A1 (en) | 2011-05-26 |
US7973136B2 (en) | 2011-07-05 |
CA2625998A1 (en) | 2007-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007044616A3 (en) | Optimized anti-cd30 antibodies | |
WO2008022152A3 (en) | Optimized antibodies that target cd19 | |
WO2008091954A3 (en) | Optimized cd40 antibodies and methods of using the same | |
WO2008098115A3 (en) | Optimized igf-1r antibodies and methods of using the same | |
WO2008091798A3 (en) | Optimized ca9 antibodies and methods of using the same | |
WO2008121160A3 (en) | Optimized antibodies that target cd5 | |
WO2006047350A3 (en) | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION | |
WO2007106744A3 (en) | Anti-5t4 antibodies and uses thereof | |
WO2006105062A3 (en) | Altered antibody fc regions and uses thereof | |
WO2008036688A3 (en) | Optimized antibodies that target hm1.24 | |
WO2007133290A8 (en) | Anti-ox40l antibodies and methods using same | |
WO2006083936A3 (en) | Anti-ephb2 antibodies and methods using same | |
WO2007120334A3 (en) | Methods and compositions for targeting polyubiquitin | |
WO2008079995A3 (en) | Conjugate of natriuretic peptide and antibody constant region | |
WO2007130697A8 (en) | Anti-ephb4 antibodies and methods using same | |
WO2006053301A3 (en) | Fc variants with altered binding to fcrn | |
WO2008070344A3 (en) | Compositions and methods for binding sphingosine-1-phosphate | |
WO2007033230A3 (en) | Anti-cd3 antibody formulations | |
WO2007136893A3 (en) | Anti-fgf19 antibodies and methods using same | |
WO2008060705A3 (en) | Anti-dll4 antibodies and methods using same | |
WO2007008943A3 (en) | Optimized anti-ep-cam antibodies | |
WO2006121422A8 (en) | Antibodies against clostridium difficile toxins and uses thereof | |
WO2003046560A3 (en) | Self-assembly molecules | |
WO2005010048A3 (en) | Rg1 antibodies and uses thereof | |
WO2005105844A3 (en) | Preparation of scfv antibody fragments |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006302254 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2625998 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12089384 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2008534748 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2873/DELNP/2008 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2006302254 Country of ref document: AU Date of ref document: 20061006 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006825618 Country of ref document: EP |